A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Inclusion Criteria: * mFARS ≥20 to ≤70 at baseline * Must be able to ambulate at least 10 feet in 1 minute with or without assistance (non-wheelchair). * Friedreich ataxia diagnosis (homozygous for guanine-adenine-adenine \[GAA\] repeat expansion in intron-1 of frataxin \[FXN\] gene), confirmed by clinical testing (Note: size of GAA repeat is not required for eligibility) * Consent to comply with study procedures. For participants under the age of 18 (or age of consent), parent(s)/legal guardian(s) of the participant must agree to comply with the requirements of the study, including the need for frequent and prolonged follow up; parent(s)/legal guardian(s) with custody of the participant must give their consent for participant to enroll in the study. * Difference in the mFARS at screening and baseline of no more than 4 points. * Must be able to abstain from anticoagulants and any aspirin (including 81 mg) for 30 days prior to the baseline visit and for the duration of the study; any possible discontinuation of anticoagulants should be monitored and indicated by a specialist (for example, cardiologist, neurologist, or hematologist) and discontinuation will be noted by the prescribing physician. * Must be able to abstain from potent cytochrome P450 (CYP) 3A4 inducers/inhibitors (for example, ketoconazole, rifampin, St. John's wort, grapefruit juice or any grapefruit product) for at least 30 days prior to enrollment * Must be able to swallow capsules * Males and females of chil…